Paxlovid May Help Some with Long-COVID After All
An up-close look at how patients respond to the drug at different times and doses adds nuance to a recent finding that Paxlovid does not work for long-COVID.
An up-close look at how patients respond to the drug at different times and doses adds nuance to a recent finding that Paxlovid does not work for long-COVID.
An up-close look at how patients respond to the drug at different times and doses adds nuance to a recent finding that Paxlovid does not work for long-COVID.
Read MoreThe Cleveland Clinic ReCOVer Clinic is enrolling Long COVID patients in the NIH RECOVER-VITAL clinical study.
Read MoreIn some of the most notable pharmaceutical approvals from 2023, drugs for RSV, CF, COVID-19, sickle cell disease, and opioid overdose received an FDA stamp in 2023.
Read MoreAn observational study found that patients treated with nirmatrelvir-ritonavir for acute COVID-19 showed more frequent virologic rebound compared to those not receiving the treatment.
Read MoreThe World Health Organization updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19.
Read MoreA trial emulation study of veterans with COVID-19 found that the use of the antiviral nirmatrelvir–ritonavir (Paxlovid) was not effective for reducing the risk for many post-COVID-19 conditions.
Read MorePfizer’s Paxlovid is the fourth drug—and first oral antiviral pill—approved by the FDA to treat COVID-19 in adults.
Read MoreThe US FDA has authorized the emergency use of Paxlovid (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients age 12 and older.
Read MoreAccording to data, Pfizer’s COVID-19 antiviral Paxlovid reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) with no patient deaths.
Read More